文献速递泌尿生殖PETCT

前列腺切除术后生化复发中定制PSMA-PET引导治疗的肿瘤学结局(PSICHE试验-NCT 05022914)

Oncological outcomes after tailored PSMA-PET-guided treatment in biochemical relapse after prostatectomy (PSICHE Trial-NCT 05022914).
PubMed 文献 · Radiol Med · 2025-10-13

PSICHE是一项多中心前瞻性研究,纳入159例前列腺切除术后生化复发(PSA>0.2≤1 ng/mL)患者,按预设PSMA-PET引导治疗算法分层治疗,中位随访19个月,按EAU风险分层的两组间中位无生化复发生存与无转移生存无显著差异(p=0.58和p=0.21),中位无转移生存与无ADT生存未达到,结论认为该策略结果有前景且需更长随访明确生存结局。

要点

  • PSMA-PET引导的预设治疗算法用于前列腺切除术后生化复发(PSA>0.2≤1 ng/mL)患者。
  • 中位随访19个月,按EAU标准分层的低危与高危组间中位BRFS和MFS无显著差异。
  • 中位无转移生存与无ADT生存未达到,原文认为需更长随访明确生存结局。

核心结论

  • PSMA靶向治疗策略取得了有前景的结果,避免了未筛选患者接受ADT或标准SRT的不必要毒性,但需更长随访分析以明确生存结局。

研究设计与样本

  • 多中心前瞻性研究(PSICHE,NCT 05022914),纳入159例前列腺切除术后生化复发(PSA>0.2≤1 ng/mL)患者,行68Ga-PSMA-PET分期并按预设治疗算法分组治疗。

诊断标准与关键数值

  • 生化复发定义:前列腺切除术后PSA>0.2且≤1 ng/mL。
  • 预设治疗算法:PET阴性或前列腺床阳性者行前列腺床挽救性放疗(SRT);检出盆腔淋巴结复发或寡转移性疾病者行立体定向体部放疗(SBRT);广泛多转移性疾病者建议雄激素剥夺治疗(ADT)。
  • EAU风险分层:低危为PSA倍增时间>12个月且Gleason评分<8;高危为PSA倍增时间≤12个月或Gleason评分≥8。
  • 中位随访19个月,低危与高危组间中位BRFS(p=0.58)和MFS(p=0.21)无显著差异。

临床应用与阅片要点

  • 原文结论认为PSMA靶向治疗策略结果有前景,可避免未筛选患者接受ADT或标准SRT的不必要毒性。
  • 原文结论指出需更长随访分析以明确生存结局。

局限性

  • 原文结论指出需更长随访分析以明确生存结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Next-generation imaging (NGI) (68 Ga-prostate-specific membrane antigen (PSMA)-PET) represents a cornerstone in biochemical recurrent prostate cancer management. PSICHE is a multicentric prospective study, aimed to assess oncological outcomes of a predefined tailored imaging-guided treatment.

METHODS: Patients with biochemical recurrence (BCR) after surgery (prostate-specific antigen [PSA] > 0.2 ≤ 1 ng/mL) underwent staging with PSMA-PET. A predefined treatment algorithm was proposed to all patients: prostate bed salvage radiotherapy (SRT) in case of negative or positive PET within the prostate bed, stereotactic body radiotherapy (SBRT) if pelvic nodal recurrences or oligometastatic disease were detected, and androgen deprivation therapy (ADT) was proposed in widespread polymetastatic disease. Chi-square test was used to evaluate the relationship between baseline features and the rate of positive PSMA-PET/CT.

RESULTS: One hundred and fifty-nine patients were enrolled. One hundred and seven patients had a PSMA negative/positive in the prostate bed; pelvic nodal disease or oligometastatic metastatic disease was detected in 39 and 10 patients, respectively. Three patients had a polymetastatic disease. Seventeen patients underwent observation because of prior postoperative radiotherapy (RT)/treatment refusal. Eighty-eight patients were treated with SRT, and SBRT was performed in 49 patients with pelvic or extrapelvic oligometastatic disease. Stratifying patients according to EAU criteria (low risk: PSA doubling time > 12 months and Gleason score < 8; high risk: PSA doubling time ≤ 12 months or Gleason score ≥ 8) after a median follow-up of 19 months in the overall population, median BRFS and MFS were not significantly different between the two risk subgroups (p = 0.58 and p = 0.21, respectively). Median metastasis-free and ADT-free survival were not reached.

CONCLUSIONS: A PSMA-targeted treatment strategy led to promising results, avoiding unnecessary toxicity from ADT or standard SRT administered in unselected patients. Analysis after longer follow-up is needed to clarify survival outcomes.

来源:Radiol Med,查看原文。版权归原作者所有。

引用

  1. Francolini G, Garlatti P, Di Cataldo V, et al. Oncological outcomes after tailored PSMA-PET-guided treatment in biochemical relapse after prostatectomy (PSICHE Trial-NCT 05022914). Radiol Med. 2025. PMID: 41081978. doi:10.1007/s11547-025-02107-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。